Effects of doxofylline as an adjuvant on severe exacerbation and long-term prognosis for COPD with different clinical subtypes.

Abstract

OBJECTIVE:

This study aimed to investigate the effectiveness of doxofylline as an adjuvant in reducing severe exacerbation for different clinical subtypes of chronic obstructive pulmonary disease (COPD).

METHODS:

The clinical trial was an open-label non-randomized clinical trial that enrolled patients with COPD. The patients were divided into two groups (doxofylline group[DG] and non-doxofylline group[NDG]) according to whether the adjuvant was used. Based on the proportion of inflammatory cells present, the patients were divided into neutrophilic, eosinophilic, and mixed granulocytic subtypes. The rates of severe acute exacerbation, use of glucocorticoids, and clinical symptoms were followed up in the first month, the third month, and the sixth month after discharge.

RESULTS:

A total of 155 participants were included in the study. The average age of the participants was 71.2  ±  10.1 years, 52.3% of the patients were male, and 29.7% of the participants had extremely severe cases of COPD. In the third month after discharge the numbers of patients exhibiting severe exacerbation among the neutrophilic subtype were 5 (6.6%) in the DG versus 17 (22.4%) in the NDG (incidence rate ratio[IRR] = 0.4 [95% CI: 0.2-0.9] P = 0.024). In the sixth month after discharge, the numbers were 3 (3.9%) versus 13 (17.1%; IRR = 0.3 [95%; CI: 0.1-0.9], P = 0.045), and those for the eosinophilic subtype were 0 (0.0%) versus 4 (14.8%), P = 0.02. In the eosinophilic subtype, the results for forced expiratory volume in the first second and maximal mid-expiratory flow were significantly higher in the DG. The mean neutrophil and eosinophil levels were significantly lower than in the NDG among the neutrophilic subtype, and the neutrophil percentage was lower than in the NDG among the eosinophilic subtype. At the six-month follow-up, the dose adjustment rates of the neutrophilic and eosinophilic subtypes showed a significant difference (P< 0.05).

CONCLUSIONS:

As an adjuvant drug, doxofylline has a good therapeutic effect on patients with the neutrophilic and eosinophilic clinical subtypes of COPD. It can reduce the incidence of severe exacerbation, the use of glucocorticoids, and inflammatory reactions in the long term (when used for a minimum of 3 months).

• Authors: Mei-Feng Chen, Wei He, De-Sheng Huang, Hui Jia, Zhao-Shuang Zhong, Nan Li, Shan-Shan Li, Shu-Yue Xia
• Journal: The clinical respiratory journal (Clin Respir J) Vol. 17 Issue 9 Pg. 851-864 (Sep 2023) ISSN: 1752-699X [Electronic] England
• PMID: 37562435 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.

Chemical References

• Glucocorticoids

Topics

• Humans
• Male
• Middle Aged
• Aged
• Aged, 80 and over
• Female
• Glucocorticoids (therapeutic use)
• Disease Progression
• Pulmonary Disease, Chronic Obstructive
• Prognosis
• Eosinophils
• Forced Expiratory Volume